Alcon announced its innovative lineup of new product offerings, showcasing its commitment to improving surgical efficiency and patient outcomes at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 25-28, in Los Angeles.
This year’s event will feature Alcon’s most recent product introductions across specialty areas ranging from cataract and refractive to glaucoma and retina, as well as several peer-to-peer symposia, in-booth demonstrations, and more.
Over 50 studies will be presented at this year’s event, including Phase 3 findings on Alcon’s pharmaceutical candidate for the treatment of the signs and symptoms of dry eye disease (DED), AR-15512 (acoltremon ophthalmic solution) 0.003% and new comfort-related data that supports performing phacoemulsification at a lower intraocular pressure (IOP).
"With an unprecedented showcase of cutting-edge innovation and clinical data on display, we are introducing new technologies that will shape the future of ophthalmology," said Sergio Duplan, senior vice president, president, Americas, for Alcon. “Our commitment to developing first-of-its-kind innovations that equip eye care professionals with essential tools for exceptional care and excellent outcomes for patients is unwavering.”
Innovation in focus
In addition to product demos at the booth, Alcon is presenting the first-hand perspective of several of the industry’s leading ophthalmologists through its new peer-to-peer in-booth presentation series, Innovation in Focus.
These surgeons will share the impact that Alcon’s latest innovations, including UNITY VCS/CS, PanOptix Pro, Voyager DSLT, wavelight plus, and Adi have had on their practice. A total of 13 presentations will take place from Friday, April 25 through Sunday, April 27. For the full schedule, visit www.MyAlconatASCRS.com.
Symposia showcasing cutting-edge innovations
A special breakfast symposium will highlight Alcon intraocular lenses (IOLs). The event – Current IOLs: What does new comparative clinical data say about efficacy and efficiency? – will be presented by Alcon Medical Affairs and moderated by Robert Melendez, MD. It will feature panelists Clayton Blehm, MD, Zach Balest, MD, and Dagny Zhu, MD. (Saturday, April 26, 6:30 a.m. PDT, LA Convention Center, Rm# 408 AB).
In addition to the breakfast symposium, the Alcon Medical Affairs team will host scientific exchange presentations at the Alcon booth. A complete schedule and registration are available here or at the Alcon booth.
ASCRS attendees are also invited to join a special lunch symposium, Experience Extraordinary: Better Together with Unity VCS/CS and PanOptix Pro. The symposium will be moderated by Rosa Braga Mele, MD, featuring panelists Nicole Fram, MD, Morgan Micheletti, MD, Matt Rauen, MD, and Lawrence Woodard, MD. (Saturday, 11:30 a.m. PDT, LA Convention Center, Eye World Theater).
Pivotal data to be presented for AR-15512 (acoltremon ophthalmic solution) 0.003%, an investigational pharmaceutical product for the signs and symptoms of DED
Investigators studying Acoltremon 0.003%, Alcon’s pharmaceutical dry eye pipeline candidate and first-in-class transient receptor potential melastatin 8 (TRPM8) agonist, will present Phase 3 results from their pivotal COMET-2, COMET-3, and COMET-4 clinical studies.1-5 Five scientific papers will be presented:
- Laura M. Periman, MD, Guru Pattar, MD, and Euguene B. McLaurin, MD, et al. (April 26, 4:10 p.m. PDT, LA Convention Center, Meeting Room Level, 505)1
- Preeya Gupta, MD, James Paauw, MD, and Mitchell Shultz, MD, et al. (April 26, 4:20 p.m. PDT, LA Convention Center, Meeting Room Level, 505)2
- Laura M. Periman, MD, Kenneth Kenyon, MD, and Blair Boehmer, MD, et al. (April 26, 4:37 p.m. PDT, LA Convention Center, Meeting Room Level, 505)3
- David Wirta, MD, Gary Jenkins, MD, and James Paauw, MD, et al. (April 27, 10:38 a.m. PDT, LA Convention Center, Meeting Room Level, 512)4
- David Wirta, MD, Sheila Garcia-Santana, MD, and David Almeida, MD, et al. (April 28, 10:10 a.m. PDT, LA Convention Center, Meeting Room Level, 504)5
Additional studies highlighting impact of Alcon innovation on patient outcomes include:
- Evidence supports that 3-month postoperative visual acuity between Clareon Monofocal and Clareon Toric are non-inferior to those of Light Adjustable Lenses (LAL), when targeting mini-monovision. More information about this study will be presented in a scientific paper authored by Clayton Blehm, MD. (April 27, 10:00 a.m. PDT, LA Convention Center Level 2, 505)6
- In refractive outcomes, new evidence supports that at 6-months post-op, Contoura with Phorcides outperforms SMILE^ across multiple visual metrics including UDVA, CDVA, low contrast (LC) UDVA, LC best corrected visual acuity, as well as lower incidence of higher order aberrations, trefoil and residual manifest cylinder. A scientific paper presented by Charisma Evangelista, MD, at this year’s conference will further highlight the findings of this study. (April 27, 4:05 p.m. PDT, LA Convention Center, Meeting Room Level, 512)7
- In cataract surgery outcomes, new findings indicate that, compared to procedures performed at a higher IOP setting (65 mmHg), performing the procedure at a lower IOP setting (24 mmHg) reduces patient pain and the incidence of reverse pupillary block, while also eliminating the need for additional medication to manage intraoperative breakthrough discomfort. Further details on this study can be found at the conference in two scientific papers presented by Matthew Rauen, MD. (April 26, 8:35 a.m. PDT, LA Convention Center Meeting Room Level, 510)8,9
- Data indicate that when used with ARGOS Biometer measurements in patients with history of refractive surgery, the Barrett True Axial Length (BTAL) formula for calculating IOL power has statistically superior (p=0.05) accuracy compared to the Barrett Universal II (BU II) formula in short eyes, with similar accuracy in medium and long eyes. Dr. Hanna John Shammas will present the findings of this prospective study led by Tanner Ferguson, MD, in a scientific paper at this year’s conference. (April 27, 8:05 a.m. PDT, LA Convention Center, Level 2, 510)10
Alcon Unveils Adi: A Cutting-Edge Digital Platform Connecting the Clinic to the OR
As part of Alcon’s commitment to providing complete, connected care, the company is introducing Adi, the digital platform within Alcon Vision Suite, that enhances clinical and workflow efficiency.
Adi offers a growing suite of cloud-based digital tools that connect clinic workflows with the surgery center. By linking patient and surgery data from the clinic to the OR, Adi helps ensure the right products are in the right place at the right time.
The first set of product modules will be available for demo at the Alcon booth:
- Clinic Connect: A web-based platform where clinics can enter patient and IOL information for upcoming surgeries, informing the surgery center exactly what's needed and when.
- Inventory Manager: Quickly scan and inventory Alcon IOLs and Custom Pak with a handheld scanner, so the surgery center knows what Alcon inventory is needed before surgery day.
- Online Store: Easily order missing IOLs and Custom Pak with just a few clicks, so everything arrives on time for surgery.
Additional educational opportunities, experiences and demos for surgeons will be available at the Alcon booth #1815.
To register for Alcon-sponsored events and learn more about the Alcon products on display at ASCRS, please visit www.MyAlconatASCRS.com.